ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 87 filers reported holding ALX ONCOLOGY HLDGS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,490 | -41.9% | 10,727 | -9.0% | 0.03% | -40.4% |
| Q2 2023 | $88,573 | +117.3% | 11,794 | +30.8% | 0.05% | +136.4% |
| Q1 2023 | $40,766 | -71.0% | 9,019 | -27.8% | 0.02% | -69.9% |
| Q4 2022 | $140,695 | -6.8% | 12,484 | -20.8% | 0.07% | +21.7% |
| Q3 2022 | $151,000 | +18.9% | 15,756 | +0.7% | 0.06% | +27.7% |
| Q2 2022 | $127,000 | +16.5% | 15,641 | +141.9% | 0.05% | -4.1% |
| Q1 2022 | $109,000 | -25.9% | 6,465 | -5.5% | 0.05% | -12.5% |
| Q4 2021 | $147,000 | -43.5% | 6,844 | +94.1% | 0.06% | -50.9% |
| Q3 2021 | $260,000 | +28.1% | 3,526 | -5.2% | 0.11% | +37.3% |
| Q2 2021 | $203,000 | -26.7% | 3,718 | -1.1% | 0.08% | -29.1% |
| Q1 2021 | $277,000 | -12.9% | 3,758 | +1.9% | 0.12% | -11.4% |
| Q4 2020 | $318,000 | – | 3,688 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |